MedTrace Logo

MK0767 and Sulfonylurea Combination Study (0767-027)

NCT00543491 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2015-06-12

No results posted yet for this study

Summary

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MK0767

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00543491 on ClinicalTrials.gov